Not known Facts About Lp-PLA2-IN-1
Contraindicated (one)bortezomib will enhance the amount or influence of mavacamten by impacting hepatic enzyme CYP2C19 metabolism. Contraindicated. Sturdy or reasonable CYP2C19 inhibitors may possibly boost mavacamten systemic exposure, causing coronary heart failure resulting from systolic dysfunction.Cure causes peripheral neuropathy (predominant